Address
OrbiMed Advisors LLC
767 Third Avenue
30th Floor
New York, NY 10017
United States
Phone
Website
Recent investment activity
KANDO id: 29979
Corporate information
Founders
Official name
OrbiMed Advisors Limited Liability Company
Registration country
Company type
American investment firm focused on making public and private investments in the healthcare and biotechnology industries.Overview
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
Funding rounds
Investment preferences
Investment activity status
Active investor
Selected investments
Displaying 76 - 100 of 114| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series F | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series E Follow-on investment | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series D Follow-on investment | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series C Initial investment | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series B | |||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Adiana Inc | Series D | ||||
|
Adimab LLC | Developer of a human antibody discovery platform in yeast. | Series D | |||
|
|
Adolor Corp | N/A | ||||
|
|
Aerogen | Medical device and drug delivery company | N/A | |||
|
|
Agensys Inc | Series D | ||||
|
|
Anthera Pharmaceuticals Inc | N/A | ||||
|
Armo BioSciences Inc | Late-stage immuno-oncology company. | Series C-1 Follow-on investment | |||
|
|
Arteaus Therapeutics LLC | A product-focused biotechnology company developing a novel treatment for migraine prevention. | N/A | |||
|
|
ARYx Therapeutics Inc | N/A Initial investment | ||||
|
|
Athersys Inc | Develops therapeutic products to treat significant and life-threatening diseases. | N/A | |||
|
|
Avalon Pharmaceuticals Inc | Biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. | N/A | |||
|
|
Biolex Therapeutics Inc | Series D | ||||
|
|
BioMarin Pharmaceutical Inc | N/A | ||||
|
Blossomhill Therapeutics Inc | Biotechnology company focused on oncology and autoimmune disorders. | Series A Initial investment | |||
|
|
Cell Therapeutics Inc | Biotherapeutics for cancer treatment. | N/A | |||
|
|
Cleave Biosciences Inc | Drug development company focused on novel targets in cellular protein homeostasis pathways | Series A | |||
|
|
Cleave Biosciences Inc | Drug development company focused on novel targets in cellular protein homeostasis pathways | N/A | |||
|
Complete Genomics Inc | Series E | ||||
|
|
Complete Genomics Inc | Series D | ||||
|
|
Enobia Pharma Corp | Series B |